Semaglutide & cardiovascular outcomes: the SELECT trial

SELECT: cardiovascular outcomes for a weight-loss drug

Published in 2023, SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, but without diabetes, and followed them a mean of about 40 months. Semaglutide 2.4 mg reduced the primary composite endpoint — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — by 20% (hazard ratio 0.80) versus placebo. This was the first trial to show a weight-management GLP-1 prevents cardiovascular events, independent of diabetes.

Blood pressure, lipids, and inflammation

Beyond events, semaglutide moves cardiometabolic markers. Across the STEP program and real-world cohorts, patients saw meaningful reductions in systolic blood pressure (roughly 5–6 mmHg), triglycerides, LDL cholesterol, HbA1c, and C-reactive protein — an inflammation marker linked to cardiovascular risk. These changes are largely weight-loss mediated.

What SELECT does and doesn't prove

SELECT was a landmark, but reading it precisely matters. It enrolled people who already had established cardiovascular disease plus overweight or obesity, and specifically excluded people with diabetes. That means its 20% event reduction applies most directly to secondary prevention — reducing a second event in people who've already had cardiovascular disease — rather than to primary prevention in otherwise healthy people carrying extra weight. The event reduction is also larger than weight loss alone would fully explain in some analyses, suggesting benefits through inflammation, blood pressure, and the vasculature directly. Critically, SELECT studied the FDA-approved brand product; its findings cannot simply be assumed to transfer to compounded semaglutide, which has no comparable outcomes trial.

The financial case for treating obesity as cardiovascular disease

A cardiovascular event can cost tens of thousands of dollars acutely and far more over time. A patient who avoids one generates savings that dwarf even brand semaglutide's ~$16,000 annual cost, let alone a $1,740 flat-rate compounded program. This is the argument payers are slowly accepting: treating obesity aggressively can be cheaper than treating its downstream disease. If you have established cardiovascular disease alongside overweight or obesity, your prescriber can now cite a 17,000-patient trial to a medical reviewer — the strongest lever in many prior-authorization requests.

Frequently asked questions

Using SELECT in an insurance and coverage conversation

The SELECT trial changed more than the clinical understanding of semaglutide; it changed the insurance argument, and knowing how to use it can be worth thousands of dollars for the right patient. Before SELECT, insurers often treated obesity as a lifestyle condition and weight-management drugs as cosmetic, an easy basis for denial. After SELECT, semaglutide has level-1 evidence that it prevents heart attacks and strokes in people with established cardiovascular disease and excess weight. For a patient with that profile, this transforms a prior-authorization request from a plea into an evidence-backed medical-necessity argument. The practical mechanics: your prescriber documents the qualifying cardiovascular condition with the appropriate diagnosis codes, references the SELECT outcome in the medical-necessity letter, and frames semaglutide as cardiovascular risk reduction rather than weight loss alone. If the first request is denied, an internal appeal citing the specific trial evidence and the plan own coverage criteria is the next step, followed by external review if needed. This path applies to the FDA-approved brand product, which is what insurance covers; compounded semaglutide is essentially never reimbursed, so the SELECT-based coverage argument is precisely the reason an insured cardiovascular patient should pursue brand coverage before defaulting to cash-pay compounded. The evidence that makes the brand worth pursuing is the same evidence that does not automatically transfer to the compounded product.

What SELECT means for how long you stay on treatment

The cardiovascular findings reframe a question that pure weight-loss data leave open: how long should treatment continue? If semaglutide were only a weight-loss tool, the logic of stopping once a goal is reached would be tempting, despite the regain data. But SELECT reframes the drug, for the right patient, as cardiovascular risk-reduction therapy, and risk reduction is inherently ongoing — the benefit accrues while you take it and fades when you stop, the same pattern seen with statins and blood-pressure medication. For a patient with established cardiovascular disease and excess weight, that shifts the default from a time-limited course toward indefinite therapy, which in turn makes the pricing structure a multi-year decision rather than a monthly one. A flat-rate program that holds its price across years is worth more to someone likely to stay on treatment for cardiovascular reasons than to someone using it briefly. The evidence also sharpens the coverage conversation: a patient whose prescriber frames the request around SELECT and documented cardiovascular disease has a materially stronger prior-authorization case for the brand product than one citing weight alone. None of this transfers automatically to compounded semaglutide, which was not studied in SELECT — a distinction that matters precisely because the strongest reason to stay on treatment long-term is also the strongest reason to pursue the approved product through insurance where possible. The practical takeaway is to treat duration as a clinical decision informed by your cardiovascular risk, and to let that expected duration drive how heavily you weight pricing predictability when you choose a program.

References

1. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023.
2. Wilding JPH, et al. STEP 1 cardiometabolic secondary endpoints. N Engl J Med. 2021.
3. Novo Nordisk. Wegovy Prescribing Information — cardiovascular indication.
4. RxCompareHub July 2026 price report.

Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.

Keep reading